Company News: Cogstate has released its 2022 Annual Report to Shareholders. – READ THE REPORT

Our Solutions

Clinical Trials

Solutions to optimize clinical outcome assessments to better measure drug efficacy and safety

Healthcare

Tools to detect patient cognitive impairment and change throughout the continuum of care

Academic Research

Technology for researchers studying cognition, from academics to public-private partnerships

Why Cogstate

Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerized cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture.

The company’s clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.

Cogstate Digital Assessment

Cogstate’s innovative digital assessments are used worldwide to simplify the measurement of cognition. Our sensitive, rapid, and reliable computerized tests provide valuable brain health insights for researchers, physicians, and patients.

2000+
Academic & Clinical Research Trials
2m+
Tests Administered
20+
Years of Experience

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch